Cefixime Dose for Gonorrhea
Cefixime 400 mg orally as a single dose is FDA-approved for uncomplicated gonorrhea, but it is NO LONGER recommended as first-line therapy due to rising resistance and inferior efficacy compared to ceftriaxone, particularly for pharyngeal infections. 1
Current Treatment Landscape
The FDA label approves cefixime 400 mg as a single oral dose for uncomplicated cervical/urethral gonorrhea 1. However, CDC guidelines have evolved significantly away from this recommendation due to antimicrobial resistance concerns.
Why Cefixime Fell Out of Favor
The 2012 CDC update explicitly removed cefixime as a first-line regimen 2. The critical issues are:
- Inferior bactericidal levels: The 400 mg oral dose does not provide bactericidal levels as high or sustained as intramuscular ceftriaxone 250 mg 2
- Poor pharyngeal efficacy: Cefixime demonstrates limited effectiveness for pharyngeal gonorrhea, with cure rates of only 81-89% compared to 97-98% for urogenital sites 3
- Rising MICs: Significant increases in cefixime minimum inhibitory concentrations (MICs) were observed, particularly in the Western U.S. and among men who have sex with men 2
- Resistance trajectory: The pattern mirrors the early emergence of fluoroquinolone resistance, suggesting impending clinical failures 2
When Cefixime May Be Considered
Cefixime 400 mg can only be used as an alternative when ceftriaxone is unavailable, and this requires specific conditions 2:
- Must be combined with azithromycin 1 g orally (preferred) or doxycycline 100 mg twice daily for 7 days
- Mandatory test-of-cure in 1 week (culture-based, not just NAAT)
- Should NOT be used for pharyngeal infections given the 11-19% failure rate 3
Critical Caveat on Pharyngeal Infections
Recent data confirm cefixime's inadequacy for pharyngeal gonorrhea. A 2024 randomized trial showed that cefixime 800 mg plus doxycycline had 100% treatment failures at pharyngeal sites, while achieving 100% cure for urogenital/rectal sites 4. The meta-analysis demonstrates only 89% cure rate for pharyngeal infections with 400 mg and 81% with 800 mg 3.
Pediatric Dosing
For children ≥6 months with uncomplicated gonorrhea 1:
- 8 mg/kg/day of suspension (maximum 400 mg)
- Can be given as single daily dose or divided into 4 mg/kg every 12 hours
- Children >45 kg: use adult dose of 400 mg
Important: The ophthalmology guidelines for gonococcal conjunctivitis in children specify ceftriaxone 25-50 mg/kg IM (not exceeding 250 mg) as the treatment of choice, NOT cefixime 5.
Resistance Monitoring
The evidence shows concerning trends:
- Historical studies from 1991-1993 showed 96-98% cure rates with cefixime 400 mg 6, 7, 8
- By 2012, CDC surveillance detected rising MICs prompting guideline changes 2
- A 2023 meta-analysis confirmed declining effectiveness, particularly at pharyngeal sites 3
Bottom Line Algorithm
For uncomplicated urogenital/rectal gonorrhea in adults:
- First-line: Ceftriaxone 500 mg IM once (per 2021 guidelines, though not in provided evidence, the 2012 guideline shows 250 mg) 2
- If ceftriaxone unavailable: Cefixime 400 mg PO once PLUS azithromycin 1 g PO once
- Mandatory test-of-cure at 1 week with culture
For pharyngeal gonorrhea:
- Cefixime should NOT be used
- Ceftriaxone is the only reliable option
For pediatric patients:
- Ceftriaxone 25-50 mg/kg IM (max 250 mg) is preferred
- If using cefixime: 8 mg/kg (max 400 mg) for urogenital only, not pharyngeal
The shift away from cefixime reflects the reality that maintaining ceftriaxone effectiveness is critical, as it remains the last highly effective single-dose treatment for gonorrhea at all anatomic sites 2.